Based on the improvement of user experience and continuous optimization of supply chain efficiency, JD.com 's net profit attributable to ordinary shareholders of listed companies under non-GAAP in the second quarter reached 14.5 billion yuan, a year-on-year increase of 69.0%. The net profit margin reached 5.0% for the first time, both of which significantly exceeded market expectations.
Based on the effective strategic execution in the whatsapp number in australia past six months, the continuous improvement of user experience has driven the quarterly active users and user shopping frequency to maintain double-digit growth in the second quarter. At the same time, benefiting from the continuous optimization of supply chain efficiency, as of the second quarter, JD Logistics' non-GAAP operating profit has been profitable for five consecutive quarters, and the non-GAAP operating profit margin in the second quarter hit a new high since JD Logistics went public.
In the first half of 2024, JD Health fully utilized the advantages of the pharmaceutical and health supply chain, and the pharmaceutical retail business grew strongly, and JD's brand awareness of buying medicines was further strengthened. During this period, JD Health launched online a number of new and special medicines, including Xingqi Eye Medicine's 0.01% atropine sulfate eye drops Meiopin®, Sanofi's new drug Zhilida®, and Jinsai's new drug Meishiya®.